EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity

Aakash Desai iD, Himsikhar Khataniar, Jana G Hashash iD, Francis A Farraye iD, Miguel Regueiro iD, Gursimran S Kochhar

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae090 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Aakash Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Weight Loss, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown sustained and clinically significant weight loss in the general population. There are limited data on outcomes of its use in patients with inflammatory bowel disease (IBD).

Methods

A retrospective cohort study was conducted between June 4, 2021, and December 11, 2023, using TriNetX, a U.S. multi-institutional database in patients with obesity who had IBD compared with patients without IBD. The primary aim was to assess the mean total body weight (TBW) change between 6 and 15 months from initiation of semaglutide compared with baseline between the 2 cohorts. One-to-one (1:1) propensity score matching was performed for demographics, comorbid conditions, smoking status, and mean body mass index. A 2-sample t test was performed to assess mean TBW change from baseline, with a P value <.05 considered to be statistically significant. We also compared the risk of IBD-specific outcomes with and without semaglutide use in patients with IBD.

Results

Out of 47 424 patients with IBD and obesity, 150 (0.3%) patients were prescribed semaglutide (mean age 47.4 ± 12.2 years; mean TBW 237 ± 54.8 pounds; mean body mass index 36.9 ± 6.5 kg/m2; 66% Crohn’s disease). There was no difference in mean TBW change after initiation of semaglutide in the IBD and non-IBD cohorts (−16 ± 13.4 pounds vs −18 ± 12.7 pounds; P = .24). There was no difference in mean TBW change between 6 and 12 months (−16 ± 13 pounds vs −15 ± 11.2 pounds; P = .24) and 12 and 15 months (−20 ± 13.2 pounds vs −21 ± 15.3 pounds; P = .49) between the 2 cohorts. There was no difference in the risk of oral or intravenous steroid use and any-cause hospitalization in the semaglutide group compared with the group without semaglutide use in patients with IBD.

Conclusion

Semaglutide use is effective in patients with IBD and obesity similar to patients without IBD, with >5% mean weight loss. There was no increased risk of IBD-specific adverse events with semaglutide use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesObesityWeight LossInflammatory Bowel DiseasesHumansFemaleMaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeBody Mass IndexGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

inflammatory bowel diseaseobesitysemaglutide

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Department of Medicine, Allegheny Health Network, Pittsburgh, PA, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.

ORCID-Profile: Aakash Desai, Jana G Hashash, Francis A Farraye, Miguel Regueiro

Zitieren

APA

Desai, A., Khataniar, H., Hashash, J. G., Farraye, F. A., Regueiro, M., & Kochhar, G. S. (2025). Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae090

Vancouver

Desai A, Khataniar H, Hashash JG, Farraye FA, Regueiro M, Kochhar GS. Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae090

BibTeX
@article{Desai2025,
  author = {Desai, Aakash and Khataniar, Himsikhar and Hashash, Jana G and Farraye, Francis A and Regueiro, Miguel and Kochhar, Gursimran S},
  title = {Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae090}
}
Kostenlos starten →